Source: BioPortfolio

NBE Therapeutics: NBE to Present LateBreaking Abstract on Lead ADC Program NBE002 ROR1 at the AACR Annual Meeting

BASEL Switzerland March 13 2019 B3C newswire NBETherapeutics AG a biopharmaceutical company developing nextgeneration immunestimulatory antibodydrug conjugates iADCs for improved cancer therapy today announces that it will present a latebreaking abstrac...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Bertrand Damour's photo - CEO of NBE-Therapeutics

CEO

Bertrand Damour

CEO Approval Rating

90/100

NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer. Read more